Home › Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research
 

Keywords :   


Navidea Biopharmaceuticals Inc (NAVB) Upgraded to "Buy" by Zacks Investment Research

2016-04-09 14:25:16| Biotech - Topix.net

The firm presently has a $1.25 price objective on the biopharmaceutical company's stock. Zacks Investment Research 's price target suggests a potential upside of 9.65% from the company's previous close.

Tags: buy research investment upgraded

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
21.09Atlantic Tropical Weather Outlook
21.09Eastern North Pacific Tropical Weather Outlook
20.09Labelexpo Americas highlights, Maxcess announces acquisition and more
20.09September Cattle on Feed as expected
20.09USDA announces major investment in meat and poultry processing
20.09Atlantic Tropical Weather Outlook
20.09Eastern North Pacific Tropical Weather Outlook
20.09This weeks lesson: Weaning matters in the cattle market
More »